ReachRxResearch
Home
Research
Sign Up
Current Practices in Antenatal CMV Testing and Management in Belgium
Back to Research Hub
  1. Home
  2. Research Hub
  3. Current Practices in Antenatal CMV Testi…

Current Practices in Antenatal CMV Testing and Management in Belgium

Prenatal Diagnosis·October 8Open Access
Obstetrics & GynecologyLimited evidenceCongenital CMVCytomegalovirus InfectionCross-Sectional SurveyAntiviralAdultValtrexValacyclovir

Summary

View source

What was studied

An online survey of 298 Belgian antenatal care practitioners (obstetricians, midwives, GPs, fetal medicine specialists) conducted Sept–Nov 2024 to describe current practices in antenatal CMV testing, valaciclovir prescribing, and termination of pregnancy (TOP) decisions, in a setting where universal screening is not recommended and testing is not reimbursed.

Key findings

89.4% of respondents reported ordering antenatal CMV testing despite no national recommendation or reimbursement; 51.7% of fetal medicine specialists prescribed valaciclovir routinely; TOP was reported to occur even without severe fetal involvement, and cost was the leading barrier to both testing and treatment.

Study limitations

Survey responses reflect self-reported perceptions rather than verified clinical records, introducing social desirability and recall bias; the sample was drawn from practitioners who chose to respond, risking selection bias; findings may not be representative of all Belgian practitioners or generalizable to other healthcare systems.

Clinical implications

Given widespread off-guideline CMV testing and variable valaciclovir use, clinicians should be aware that practice is highly heterogeneous; updated national guidance and reimbursement policies are needed to standardize counseling—especially around TOP decisions in cases without severe fetal involvement.

Caveats

  • Findings are based on practitioner self-report and reflect perceived practice, not audited clinical outcomes or patient-level data
  • The study captures practices around TOP without objective data on fetal severity thresholds used, making it difficult to assess clinical appropriateness of decisions
  • The survey was limited to Belgian practitioners in a specific healthcare funding context (no reimbursement, no universal screening policy), limiting generalizability to other countries

Related Questions

Explore related topics

What is the evidence for valaciclovir to prevent vertical CMV transmission in pregnancy?How should clinicians counsel pregnant patients after primary CMV infection regarding fetal outcomes?What are current international guidelines on antenatal CMV screening and management?

Publication Details

Year
2026
Journal
Prenatal Diagnosis
Sample Size
n=298
Source
View article
Keep scrolling
More content below.
Up Next